| Autor: |
Ahmad Samir Abdel-Hafez, Mohamed Abu-elnaga Selem, Hany Hafez Lotfy, Mohamed Ali Elsaied, Ashraf Ibrahim Zaki, Osama Mohamed Nawar, Amany M.A. Ibrahim, Marwa Abdel-Rahman Sakr, Mohamed Emam Emam, Ahmed Omar Elkady, Ahmad Rashad Fatoh, Magdy Amin Mubark, Eman M. Hasan, Mohamed Abdel-Salam Elgohary, Mohamed Farouk Ahmed, Mohamed Saeed Abd-aal, Mahmoud Moustafa Hamada, Mohamed Muawad Shehata, Mohamed Thabet Elnagar, Taimour Mohamed Abdel-Hamid, Raafat Zaher Abdel-Rahman, Mohamed G. Seadawy, Mohamed Bakr Elaatar, Sherine Helmy, Tarek Refaat Elnagdy |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.05.19.21257429 |
| Popis: |
BackgroundCOVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection..MethodsThis is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings.ResultsTwo hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, pConclusionSofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with the new treatment protocols. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
